Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  Impax Laboratories Inc    IPXL

Delayed Quote. Delayed  - 10/26 10:00:00 pm
21.35 USD   -2.06%
10/12 IMPAX LABORATOR : Research Reports on Drug Makers Equities -- Bristo..
10/10 IMPAX ASSET MAN : Assets Rise By More Than Half In Financial Year
10/04 IMPAX LABORATOR : to Report Third Quarter 2016 Results on November 9..
News SummaryMost relevantAll newsSector news 

Impax Laboratories Inc : Impax Laboratories to Present at the UBS Global Healthcare Conference

share with twitter share with LinkedIn share with facebook
share via e-mail
05/20/2013 | 01:35pm CEST

Impax Laboratories, Inc. (NASDAQ: IPXL) today announced that the Company will present at the UBS Global Healthcare Conference on Wednesday, May 22, at 9:00 a.m. Eastern Standard Time. The conference will be held at the Sheraton New York Hotel.

Individuals may listen to the live or an archived presentation made at the conference, which will be posted in the investor relations section of the Company's web site at www.impaxlabs.com. This presentation will be archived on the Company's web site for 30 days.

About Impax Laboratories, Inc.

Impax Laboratories, Inc. (Impax) is a technology based specialty pharmaceutical company applying its formulation expertise and drug delivery technology to the development of controlled-release and specialty generics in addition to the development of central nervous system disorder branded products. Impax markets its generic products through its Global Pharmaceuticals division and markets its branded products through the Impax Pharmaceuticals division. Additionally, where strategically appropriate, Impax develops marketing partnerships to fully leverage its technology platform and pursues partnership opportunities that offer alternative dosage form technologies, such as injectables, nasal sprays, inhalers, patches, creams and ointments. For more information, please visit the Company's Web site at: www.impaxlabs.com.

Impax Laboratories, Inc.
Mark Donohue, 215-558-4526
Investor Relations and Corporate Communications

© Business Wire 2013
share with twitter share with LinkedIn share with facebook
share via e-mail
10/13 IMPAX LABORATORIES : to Report Third Quarter 2016 Results on November 9, 2016
10/12 IMPAX LABORATORIES : Research Reports on Drug Makers Equities -- Bristol-Myers S..
10/10 IMPAX ASSET MANAGEMENT : Assets Rise By More Than Half In Financial Year
10/04 IMPAX LABORATORIES : to Report Third Quarter 2016 Results on November 9, 2016
09/22 IMPAX LABORATORIES : Launches Generic Version of Metadate CD® (Methylphenidate H..
09/07 IMPAX LABORATORIES : to Present at the Morgan Stanley Global Healthcare Conferen..
09/01 IMPAX LABORATORIES : Richard A. Bierly Appointed to Impax Laboratories Board of ..
08/30 IMPAX LABORATORIES : Provides Update on Epinephrine Injection, USP Auto-Injector
08/29 Mylan to launch generic EpiPen at half the price of original
08/29 IMPAX LABORATORIES : Issues Voluntary, Nationwide Recall for One Lot of Lamotrig..
More news
Sector news : Pharmaceuticals - NEC
10/26 GLAXOSMITHKLINE : British imports of cheap medicines dry up as pound falls
10/26DJGlaxo Profit Jumps on Weaker Pound
10/26 Bayer third-quarter profit beats forecasts on pharma, pesticides
10/25DJMERCK : Profit Rises on Cancer Drugs, Vaccines
10/25DJMERCK : Revenue and Profit Rise on Cancer Drugs, Vaccines -- Update
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
10/18 VALEANT : Another Philidor?
09/30 Healthcare ratings roundup - upgrades/downgrades
08/30 OPKO Health Is A Buy At $9 - Cramer's Lightning Round (8/29/16)
08/29 EPIPEN : Facts Versus Opinion; With Cost-Benefit Analysis
08/25 Shocked! Mylan, Biotechs Swoon After Hillary's Statement
Financials ($)
Sales 2016 913 M
EBIT 2016 191 M
Net income 2016 76,7 M
Debt 2016 450 M
Yield 2016 -
P/E ratio 2016 40,16
P/E ratio 2017 10,55
EV / Sales 2016 2,26x
EV / Sales 2017 1,84x
Capitalization 1 610 M
More Financials
Duration : Period :
Impax Laboratories Inc Technical Analysis Chart | IPXL | US45256B1017 | 4-Traders
Full-screen chart
Technical analysis trends IMPAX LABORATORIE...
Short TermMid-TermLong Term
Technical analysis
Income Statement Evolution
More Financials
Mean consensus HOLD
Number of Analysts 16
Average target price 29,4 $
Spread / Average Target 35%
Consensus details
EPS Revisions
More Estimates Revisions
George Frederick Wilkinson President, Chief Executive Officer & Director
Robert L. Burr Chairman
Andrew Schaschl Senior Vice President-Global Operations
Bryan M. Reasons Chief Financial Officer & Senior VP-Finance
Vishal K. Gupta CSO, Senior Vice President-Research & Development
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON11.53%311 781
ROCHE HOLDING LTD.-17.44%198 222
PFIZER INC.0.37%195 799
NOVARTIS AG-16.42%191 921
MERCK & CO., INC.15.24%171 305
More Results